Related Experiment Videos
ECT as a treatment for depression in Huntington's disease
N G Ranen1, C E Peyser, S E Folstein
1Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-7281.
The Journal of Neuropsychiatry and Clinical Neurosciences
|January 1, 1994
Summary
Electroconvulsive therapy (ECT) can effectively treat depression in Huntington's disease (HD) patients resistant to medication. While some symptoms like apathy showed less improvement, ECT offers a valuable option for managing severe depression in HD.
Area of Science:
- Neuroscience
- Psychiatry
- Neurology
Background:
- Huntington's disease (HD) is a progressive neurodegenerative disorder.
- Depression is a common and debilitating comorbidity in HD patients.
- Pharmacological treatments for depression in HD often have limited efficacy or significant side effects.
Observation:
- This study reviewed 6 patients with Huntington's disease experiencing depression.
- All patients had previously shown no response to pharmacologic interventions for their depression.
- Five patients met criteria for major depression, and one for bipolar disorder, depressed.
Findings:
- Five out of six patients with Huntington's disease experienced significant improvement in depressive symptoms after electroconvulsive therapy (ECT).
- Patients with prominent delusions exhibited the most substantial response to ECT.
- Apathy and irritability showed a less pronounced improvement compared to other depressive symptoms.
Implications:
- Electroconvulsive therapy (ECT) should be considered a viable treatment option for managing depression in Huntington's disease (HD), especially in treatment-resistant cases.
- ECT may be particularly beneficial for HD patients with psychotic features, such as delusions.
- Further research is warranted to optimize ECT protocols and understand its long-term effects on both mood and motor symptoms in HD.